The data uncover broad optimism as well as stark regional disparities and cultural obstacles in the West that must be ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Bayer now says it expects to make €3 billion ... results of the phase 3 ARASENS trial in the New England Journal of Medicine. The study showed that adding Nubeqa to standard therapy with anti ...

Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson's disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people with ...

Bayer cut its full-year earnings target after a tough agricultural market hit its crop-science division, and said it heads ...

According to The Wall Street Journal, Bayer started putting in the cotton ... More from Science We've all been there: reaching for the medicine cabinet with a splitting headache, opening the ...

Leadership Strategist Dan Pontefract covers leadership and culture. Heike Prinz of Bayer's Board of Management recently articulated the company's predicament, stating, "Bayer is currently in a ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.